3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
10
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Carcinoma, Transitional Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Carcinoma, Renal Cell
5
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Melanoma
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Lymphoma, Follicular
2
Lymphoma
2
Central Nervous System Neoplasms
2
Uveal Melanoma
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumors
1
Skin Neoplasms
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Mycosis Fungoides
1
Metastatic Urothelial Cell Cancer
1
Metastatic Solid Tumors
1
Interventions
trifluridine tipiracil drug combination
1
trebananib
1
avelumab
1
atezolizumab
1
Sunitinib
1
Paclitaxel
1
Oxaliplatin
1
Kidney Transplantation
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Kidney Diseases
×
avelumab
×
Clear all
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts